Innovations in HIV Testing (TI)
Innovations in HIV Testing to Enhance Care for Young Women and Their Peers and Partners
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Mpumalanga
-
Acornhoek, Mpumalanga, South Africa
- Medical Research Council/Wits University Rural Public Health and Health Transitions Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Eligibility Inclusion Criteria Index:
- Females ages 18-26
- Have had sex in the past 3 months and plan to have sex again in the next 3 months
- Planning on staying in the Agincourt Health and Demographic Surveillance System (AHDSS) area for the next nine months
- Able and willing to provide informed consent
- Willing to comply with study procedures
- Not known to be HIV positive (not reporting a previous positive test)
Eligibility Inclusion Criteria Peer/Partner:
- Females and Males ages 18 and older
- Able and willing to provide informed consent
- Willing to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Choice
Oraquick HIV Self Test or Clinic Based HIV Counseling and Testing (HCT)
|
This is an oral swab in home HIV test.
Receiving Counseling and Testing for HIV at the clinic.
|
|
Active Comparator: HIV Counseling and Testing
Clinic Based HIV Counseling and Testing (HCT)
|
Receiving Counseling and Testing for HIV at the clinic.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of index reporting testing uptake
Time Frame: 3 months post randomization
|
Compare between the two study arms the proportion of testing uptake at 3 months post-randomization.
Testing uptake is defined for HCT as self-report of going to the clinic and testing; and for self-test as self-report of using a self-test kit.
|
3 months post randomization
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of peer/partner referrals by the index
Time Frame: 12 months post randomization
|
Compare between the two studies arms the number of self test kits and HCT cards distributed by the index.
|
12 months post randomization
|
|
Proportion of peer/partners reporting testing uptake
Time Frame: 12 months post randomization
|
Compare between the two study arms the proportion of testing uptake by peers/partners.
Testing uptake is defined for HCT as self-report of going to the clinic and testing; and for self-test as self-report of using a self-test kit.
|
12 months post randomization
|
|
Proportion of index and peer/partners who obtain a confirmatory test, start Antiretroviral Treatment (ART) if HIV+, and obtain their Cluster of Differentiation 4 (CD4) count if HIV+
Time Frame: 12 months post randomization
|
Among participants who test positive (young women, peers and sex partners), the investigators will examine uptake of linkage to care.
|
12 months post randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Pettifor A, Lippman SA, Kimaru L, Haber N, Mayakayaka Z, Selin A, Twine R, Gilmore H, Westreich D, Mdaka B, Wagner R, Gomez-Olive X, Tollman S, Kahn K. HIV self-testing among young women in rural South Africa: A randomized controlled trial comparing clinic-based HIV testing to the choice of either clinic testing or HIV self-testing with secondary distribution to peers and partners. EClinicalMedicine. 2020 Apr 18;21:100327. doi: 10.1016/j.eclinm.2020.100327. eCollection 2020 Apr.
- Ritchwood TD, Selin A, Pettifor A, Lippman SA, Gilmore H, Kimaru L, Hove J, Wagner R, Twine R, Kahn K. HIV self-testing: South African young adults' recommendations for ease of use, test kit contents, accessibility, and supportive resources. BMC Public Health. 2019 Jan 29;19(1):123. doi: 10.1186/s12889-019-6402-4.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
Other Study ID Numbers
- 15-1361b
- 5R01HD083033 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
NCT05700734WithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
NCT05261191CompletedHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1
-
NCT03783130CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus Prevention
-
NCT00294164CompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
NCT07497594RecruitingContact With or Exposure to Human Immunodeficiency Virus
-
NCT01209117CompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and Herpesviridae
-
NCT00294918CompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
NCT07061912CompletedHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
NCT06368453CompletedHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
NCT07530198RecruitingHuman Immunodeficiency Virus | Human Immunodeficiency Virus I Infection
Clinical Trials on Oraquick HIV Self Test
-
NCT02386215Completed
-
NCT03541382Completed
-
NCT05020353CompletedHIV Infections | HIV Testing
-
NCT02846402Completed